Adamis Pharmaceuticals Corporation 8-K


Exhibit 10.1


Adamis
Announces Appointment of Meera Desai, Ph.D., to Board of Directors


Appointment
of New Director with Significant Experience in Drug Development, Licensing and Commercialization





SAN
DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment
of Meera J. Desai, Ph.D., as a new director and member of the company’s board of directors. Dr. Desai replaces Roshawn Blunt, who
retired from the Board effective October 1, 2021.


Richard
Williams, Chairman of the Board, commented: “We are pleased to welcome Dr. Desai to the Board and look forward to working with
her to pursue long-term value creation. Her substantial expertise in international pharmaceutical licensing, combined with her background
in drug development and commercialization will help us refine corporate strategy to maximize our product pipeline. I would also like
to thank Roshawn Blunt for her service on the board and for her contributions to Adamis.”


Dr.
Desai is the founder and managing partner of Silicon Valley-based Karana Biotech, a boutique advisory firm focused on guiding pharmaceutical
and biotech clients through complex international licensing, commercialization, and other strategic transactions. Prior to founding Karana
Biotech, she led corporate development efforts for AcelRx Pharmaceuticals (NASDAQ: ACRX). Previously, Dr. Desai was involved in pharmaceutical
development for Novartis Pharmaceuticals, Nektar Therapeutics, and ALZA Corporation (a division of Johnson & Johnson). She holds
a Bachelor of Arts degree in chemistry from Drew University and a Doctorate in Analytical Chemistry from Iowa State University. Dr. Desai
will serve on the Audit, Compensation, and the Nominating and Governance committees of the Adamis Board.


About
Adamis Pharmaceuticals


Adamis
Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in
various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The Company’s SYMJEPI (epinephrine)
Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The
Company’s resubmitted New Drug Application for its naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose,
is currently under FDA review. Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is
underway. For additional information about Adamis Pharmaceuticals, please visit www.adamispharmaceuticals.com.


Forward
Looking Statements


This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise
are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited
to the following statements: and other statements concerning the Company’s future operations and activities. These statements are
only predictions and involve known and unknown risks, uncertainties, and other factors, which may cause Adamis' actual results to be
materially different from the results anticipated by such forward-looking statements. We cannot assess the impact of each factor on our
business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained
in any forward-looking statements. You should not place undue reliance on any forward-looking statements. Further, any forward-looking
statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation
to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances
arising after the date of this press release. Certain of these risks and additional risks, uncertainties, and other factors are described
in greater detail in Adamis’ filings from time to time with the SEC, including its annual report on Form 10-K for the year ended
December 31, 2020 and subsequent filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available
free of charge on the SEC's website at http://www.sec.gov.


Contact:


Adamis
Investor Relations

Robert Uhl

Managing Director

Westwicke ICR

619.228.5886

robert.uhl@westwicke.com